loading
Schlusskurs vom Vortag:
$7.84
Offen:
$7.71
24-Stunden-Volumen:
18,006
Relative Volume:
0.12
Marktkapitalisierung:
$44.64M
Einnahmen:
$7.97M
Nettoeinkommen (Verlust:
$-75.74M
KGV:
-0.3057
EPS:
-24.2853
Netto-Cashflow:
$-85.33M
1W Leistung:
+2.98%
1M Leistung:
+3.12%
6M Leistung:
-81.85%
1J Leistung:
-26.50%
1-Tages-Spanne:
Value
$7.30
$7.74
1-Wochen-Bereich:
Value
$6.8242
$8.06
52-Wochen-Spanne:
Value
$3.76
$46.80

Aligos Therapeutics Inc Stock (ALGS) Company Profile

Name
Firmenname
Aligos Therapeutics Inc
Name
Telefon
(800) 466-6059
Name
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Name
Mitarbeiter
70
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ALGS's Discussions on Twitter

Vergleichen Sie ALGS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALGS
Aligos Therapeutics Inc
7.4216 44.64M 7.97M -75.74M -85.33M -24.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.90 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.79 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.87 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.94 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.19 28.51B 3.81B -644.79M -669.77M -6.24

Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-19 Eingeleitet H.C. Wainwright Buy
2023-01-06 Hochstufung Jefferies Hold → Buy
2023-01-06 Hochstufung Piper Sandler Neutral → Overweight
2022-03-23 Herabstufung Piper Sandler Overweight → Neutral
2022-01-07 Herabstufung JP Morgan Overweight → Neutral
2022-01-06 Herabstufung Jefferies Buy → Hold
2021-09-09 Eingeleitet SVB Leerink Outperform
2021-05-17 Fortgesetzt Piper Sandler Overweight
2020-11-10 Eingeleitet Cantor Fitzgerald Overweight
2020-11-10 Eingeleitet JP Morgan Overweight
2020-11-10 Eingeleitet Jefferies Buy
2020-11-10 Eingeleitet Piper Sandler Overweight
Alle ansehen

Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten

pulisher
Jun 18, 2025

Aligos Therapeutics (ALGS) Welcomes New VP of Chemistry Manufacturing Controls | ALGS Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Aligos Therapeutics Strengthens Drug Development Team: Former Kezar Executive to Drive Phase 2 Trial Progress - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics (ALGS) Issues Stock Options to New Employees | ALGS Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics Awards Major Stock Options Package: New Employees Get 26,000 Shares Under Nasdaq Rule - Stock Titan

Jun 13, 2025
pulisher
Jun 09, 2025

(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 03, 2025

5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decline in Short Interest - Defense World

Jun 02, 2025
pulisher
May 29, 2025

Clinical Stage Liver Disease Biotech Aligos Set for Major Jefferies Conference Presentation - Stock Titan

May 29, 2025
pulisher
May 28, 2025

How the (ALGS) price action is used to our Advantage - news.stocktradersdaily.com

May 28, 2025
pulisher
May 27, 2025

Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World

May 27, 2025
pulisher
May 20, 2025

Aligos Therapeutics (ALGS) Appoints New Head of Legal | ALGS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal - The Manila Times

May 20, 2025
pulisher
May 20, 2025

Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan

May 20, 2025
pulisher
May 16, 2025

Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee - Nasdaq

May 16, 2025
pulisher
May 16, 2025

Aligos Therapeutics (ALGS) Awards New Employee Stock Option Gran - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Aligos Therapeutics (ALGS) Awards New Employee Stock Option Grant | ALGS Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Aligos Therapeutics Expands Liver Disease Team with Strategic Hire, Awards 26,000 Share Options - Stock Titan

May 16, 2025
pulisher
May 11, 2025

Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - simplywall.st

May 11, 2025
pulisher
May 09, 2025

Aligos reports promising HBV treatment data at EASL Congress - Investing.com

May 09, 2025
pulisher
May 08, 2025

Aligos Therapeutics (ALGS) Showcases Promising HBV Treatment Results at EASL Congress 2025 | ALGS Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Aligos reports promising HBV treatment data at EASL Congress By Investing.com - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 07, 2025
pulisher
May 07, 2025

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results - ADVFN

May 07, 2025
pulisher
May 07, 2025

Aligos Therapeutics Reports Strong Q1 2025 Progress - TipRanks

May 07, 2025
pulisher
May 06, 2025

Aligos Therapeutics (ALGS) Reports Lower Q1 Revenue, Advances Ke - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Aligos Therapeutics Inc Reports Q1 2025 EPS of $5.12, Surpassing Estimates; Revenue Slightly Misses at $0.31 Million - GuruFocus

May 06, 2025
pulisher
May 06, 2025

ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView

May 06, 2025
pulisher
May 06, 2025

Aligos Reports Surprise $43M Profit: Breakthrough HBV Drug Shows 100% Response Rate at 96 Weeks - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Aligos Therapeutics secures $105 million in private placement - MSN

May 05, 2025
pulisher
May 04, 2025

Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday - Defense World

May 04, 2025
pulisher
May 04, 2025

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC - Defense World

May 04, 2025
pulisher
May 02, 2025

Aligos Therapeutics Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 01, 2025

Aligos Therapeutics (ALGS) Gains Buy Rating with Promising Outlo - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Aligos Therapeutics (ALGS) Coverage Initiated with Positive Outl - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Wells Fargo & Company MN Invests $869,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World

May 01, 2025
pulisher
May 01, 2025

Geode Capital Management LLC Buys 3,197 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Aligos Therapeutics Q1 2025 Earnings: Clinical Stage Biotech Reports Pre-Market May 6Key Focus Areas - Stock Titan

Apr 29, 2025
pulisher
Apr 23, 2025

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 - The Manila Times

Apr 23, 2025
pulisher
Apr 22, 2025

When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 10, 2025

ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India

Apr 10, 2025
pulisher
Apr 06, 2025

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN

Apr 06, 2025

Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.42
price up icon 0.84%
$36.14
price down icon 0.47%
$23.52
price down icon 8.23%
$95.22
price down icon 1.94%
$110.60
price up icon 0.50%
biotechnology ONC
$242.65
price down icon 0.20%
Kapitalisierung:     |  Volumen (24h):